HIV-1整合酶E157Q多态性的表型分析及其对启动整合酶抑制剂方案患者病毒学结局的影响
该多中心研究评估了法国17个HIV临床中心中未使用过整合酶抑制剂(INI)患者的整合酶序列,E157Q多态性在8528条序列中占2.7%。39例携带E157Q突变病毒的患者启动INI方案,表型分析显示不同药物在不同亚型背景下的EC50倍数变化各异,作者认为应特别关注抗逆转录病毒初治患者并优先使用多替拉韦。
要点
- E157Q多态性在8528条INI初治患者整合酶序列中占2.7%。
- 39例携带E157Q突变病毒患者启动INI方案,其中24例启动时病毒载量>50拷贝/mL。
- 表型分析显示B亚型中雷特格韦、多替拉韦、艾维雷韦EC50倍数变化分别为0.6、0.9、1.9。
核心结论
- 对39例携带E157Q突变病毒并启动INI方案患者的病毒学应答评估结合表型分析,提示应特别关注抗逆转录病毒初治患者,并在此类患者中优先使用多替拉韦。
研究设计与样本
- 多中心研究,评估法国17个HIV临床中心中INI初治患者的整合酶序列。
- 对pNL4.3和pCRF02_AG背景下的E157Q定点突变体采用重组表型试验进行评估。
主要发现
- E157Q多态性在8528条INI初治患者整合酶序列中患病率为2.7%,在B、CRF02_AG及多种非B亚型中的分布分别为1.7%、5.6%和2.2%。
- 39例携带E157Q突变病毒的INI初治患者启动INI方案,其中15例启动时病毒载量<50拷贝/mL,随访第一年除2例出现病毒短暂反弹外均维持病毒学抑制。
- 24例启动INI方案时病毒载量>50拷贝/mL,其中8例接受一线方案,第24周未达到病毒载量<50拷贝/mL的仅2例均使用艾维雷韦。
- 其余16例为病毒学失败且携带耐药病毒的经验性治疗患者,呈现多种病毒学结局,与基因型敏感性评分无关。
- 表型分析显示B亚型背景下雷特格韦、多替拉韦和艾维雷韦的EC50倍数变化分别为0.6、0.9和1.9,CRF02_AG背景下分别为1.1、1.9和2.4。
临床怎么用
- 作者认为应特别关注抗逆转录病毒初治患者,并在此类携带E157Q突变病毒的患者中优先使用多替拉韦。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the phenotypic susceptibility of the E157Q polymorphism in HIV-1 integrase (IN) and the virological outcome of patients infected with E157Q-mutated virus initiating an IN inhibitor (INI)-based regimen. METHODS: This was a multicentre study assessing IN sequences from INI-naive patients among 17 French HIV clinical centres. E157Q site-directed mutants in pNL4.3 and pCRF02_AG contexts were assessed in a recombinant phenotypic assay. RESULTS: Prevalence of the E157Q polymorphism was 2.7% among 8528 IN sequences from INI-naive patients and its distribution was 1.7%, 5.6% and 2.2% in B, CRF02_AG and various non-B subtypes, respectively. Thirty-nine INI-naive patients with E157Q-mutated virus initiated an INI-based regimen. Among them, 15 had a viral load (VL) <50 copies/mL at initiation and virological suppression was maintained during the first year of follow-up in all but two exhibiting a viral blip. Twenty-four patients had a VL > 50 copies/mL at the time of INI-based regimen initiation. Among them eight were receiving a first-line regimen and the only two patients who did not reach VL < 50 copies/mL at week 24 were receiving elvitegravir. The 16 remaining patients were ART experienced in virological failure with drug-resistant viruses displaying several virological outcomes independently of the genotypic susceptibility score. Phenotypic analyses showed a fold change in EC50 of 0.6, 0.9 and 1.9 for raltegravir, dolutegravir and elvitegravir, respectively, in a subtype B context, and 1.1, 1.9 and 2.4 for raltegravir, dolutegravir and elvitegravir, respectively, in a CRF02_AG context. CONCLUSIONS: Assessment of virological response in 39 patients initiating an INI-based regimen with E157Q-mutated virus, in combination with phenotypic analysis, suggests that particular attention should be paid to antiretroviral-naive patients and dolutegravir should be preferentially used in these patients.
引用
- Charpentier C, Malet I, Andre-Garnier E, et al. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother. 2018. PMID: 29342281. doi:10.1093/jac/dkx511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。